French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.
Identifieur interne : 004031 ( PubMed/Corpus ); précédent : 004030; suivant : 004032French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.
Auteurs : M. Andréjak ; M. Gersberg ; C. Sgro ; G. Decocq ; J D Hamel ; M. Morin ; V. GrasSource :
- Pharmacoepidemiology and drug safety [ 1053-8569 ] ; 1998.
Abstract
Synthetic coumarin (benzopyrone) was launched in France in 1988 for the adjuvant therapy of lymphoedema of the upper limb following radiosurgical treatment of breast cancer. Further to the reporting of hepatic reactions, a national survey has been carried out. The survey dealt with 22 cases reported to the pharmacovigilance regional centres and 20 to Knoll France company (five duplicate cases) up to June 1996. Thirty-four cases corresponding to an elevation of ALT over 2N and/or alkaline phosphatase over 1.5N (criteria chosen for selection in this survey) had been taken into account. Among these cases, a causal relationship was considered likely or probable for 15 of them. Two positive rechallenges were reported. The hepatic reactions observed between 2 to 6 months of treatment in two-thirds of the cases (average dose: 90 mg/day; i.e. recommended dose) was essentially cytolytic in 85% of the cases, with jaundice in 14 cases and hyperbilirubinaemia reported in five other cases. In 23 cases (68%), the increase of ALT exceeded 10N. Of the patients 41% were hospitalized. Severe liver failure with encephalopathy justified liver transplantation once and likely led to encephalopathy and fatal evolution in two other cases. The evolution was favourable in the other cases. The drug was prescribed for other uses than the registered indication in more than 50% of these cases. No risk factors could be identified in the survey. This survey provides a strong signal for potential hepatotoxicity of coumarin (likely due to the production of a reactive metabolite in some patients exhibiting a coumarin 7-hydroxylation deficiency).
DOI: 10.1002/(SICI)1099-1557(199808)7:1+
PubMed: 15073959
Links to Exploration step
pubmed:15073959Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.</title><author><name sortKey="Andrejak, M" sort="Andrejak, M" uniqKey="Andrejak M" first="M" last="Andréjak">M. Andréjak</name><affiliation><nlm:affiliation>Pharmacovigilance Regional Centre of Amiens, France. Amiens.chupharmacologie@wanadoo.fr</nlm:affiliation></affiliation></author><author><name sortKey="Gersberg, M" sort="Gersberg, M" uniqKey="Gersberg M" first="M" last="Gersberg">M. Gersberg</name></author><author><name sortKey="Sgro, C" sort="Sgro, C" uniqKey="Sgro C" first="C" last="Sgro">C. Sgro</name></author><author><name sortKey="Decocq, G" sort="Decocq, G" uniqKey="Decocq G" first="G" last="Decocq">G. Decocq</name></author><author><name sortKey="Hamel, J D" sort="Hamel, J D" uniqKey="Hamel J" first="J D" last="Hamel">J D Hamel</name></author><author><name sortKey="Morin, M" sort="Morin, M" uniqKey="Morin M" first="M" last="Morin">M. Morin</name></author><author><name sortKey="Gras, V" sort="Gras, V" uniqKey="Gras V" first="V" last="Gras">V. Gras</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:15073959</idno><idno type="pmid">15073959</idno><idno type="doi">10.1002/(SICI)1099-1557(199808)7:1+3.0.CO;2-1</idno> <idno type="wicri:Area/PubMed/Corpus">004031</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004031</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.</title><author><name sortKey="Andrejak, M" sort="Andrejak, M" uniqKey="Andrejak M" first="M" last="Andréjak">M. Andréjak</name><affiliation><nlm:affiliation>Pharmacovigilance Regional Centre of Amiens, France. Amiens.chupharmacologie@wanadoo.fr</nlm:affiliation></affiliation></author><author><name sortKey="Gersberg, M" sort="Gersberg, M" uniqKey="Gersberg M" first="M" last="Gersberg">M. Gersberg</name></author><author><name sortKey="Sgro, C" sort="Sgro, C" uniqKey="Sgro C" first="C" last="Sgro">C. Sgro</name></author><author><name sortKey="Decocq, G" sort="Decocq, G" uniqKey="Decocq G" first="G" last="Decocq">G. Decocq</name></author><author><name sortKey="Hamel, J D" sort="Hamel, J D" uniqKey="Hamel J" first="J D" last="Hamel">J D Hamel</name></author><author><name sortKey="Morin, M" sort="Morin, M" uniqKey="Morin M" first="M" last="Morin">M. Morin</name></author><author><name sortKey="Gras, V" sort="Gras, V" uniqKey="Gras V" first="V" last="Gras">V. Gras</name></author></analytic><series><title level="j">Pharmacoepidemiology and drug safety</title><idno type="ISSN">1053-8569</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Synthetic coumarin (benzopyrone) was launched in France in 1988 for the adjuvant therapy of lymphoedema of the upper limb following radiosurgical treatment of breast cancer. Further to the reporting of hepatic reactions, a national survey has been carried out. The survey dealt with 22 cases reported to the pharmacovigilance regional centres and 20 to Knoll France company (five duplicate cases) up to June 1996. Thirty-four cases corresponding to an elevation of ALT over 2N and/or alkaline phosphatase over 1.5N (criteria chosen for selection in this survey) had been taken into account. Among these cases, a causal relationship was considered likely or probable for 15 of them. Two positive rechallenges were reported. The hepatic reactions observed between 2 to 6 months of treatment in two-thirds of the cases (average dose: 90 mg/day; i.e. recommended dose) was essentially cytolytic in 85% of the cases, with jaundice in 14 cases and hyperbilirubinaemia reported in five other cases. In 23 cases (68%), the increase of ALT exceeded 10N. Of the patients 41% were hospitalized. Severe liver failure with encephalopathy justified liver transplantation once and likely led to encephalopathy and fatal evolution in two other cases. The evolution was favourable in the other cases. The drug was prescribed for other uses than the registered indication in more than 50% of these cases. No risk factors could be identified in the survey. This survey provides a strong signal for potential hepatotoxicity of coumarin (likely due to the production of a reactive metabolite in some patients exhibiting a coumarin 7-hydroxylation deficiency).</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">15073959</PMID><DateCreated><Year>2004</Year><Month>04</Month><Day>09</Day></DateCreated><DateCompleted><Year>2004</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2004</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1053-8569</ISSN><JournalIssue CitedMedium="Print"><Volume>7 Suppl 1</Volume><PubDate><Year>1998</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.</ArticleTitle><Pagination><MedlinePgn>S45-50</MedlinePgn></Pagination><Abstract><AbstractText>Synthetic coumarin (benzopyrone) was launched in France in 1988 for the adjuvant therapy of lymphoedema of the upper limb following radiosurgical treatment of breast cancer. Further to the reporting of hepatic reactions, a national survey has been carried out. The survey dealt with 22 cases reported to the pharmacovigilance regional centres and 20 to Knoll France company (five duplicate cases) up to June 1996. Thirty-four cases corresponding to an elevation of ALT over 2N and/or alkaline phosphatase over 1.5N (criteria chosen for selection in this survey) had been taken into account. Among these cases, a causal relationship was considered likely or probable for 15 of them. Two positive rechallenges were reported. The hepatic reactions observed between 2 to 6 months of treatment in two-thirds of the cases (average dose: 90 mg/day; i.e. recommended dose) was essentially cytolytic in 85% of the cases, with jaundice in 14 cases and hyperbilirubinaemia reported in five other cases. In 23 cases (68%), the increase of ALT exceeded 10N. Of the patients 41% were hospitalized. Severe liver failure with encephalopathy justified liver transplantation once and likely led to encephalopathy and fatal evolution in two other cases. The evolution was favourable in the other cases. The drug was prescribed for other uses than the registered indication in more than 50% of these cases. No risk factors could be identified in the survey. This survey provides a strong signal for potential hepatotoxicity of coumarin (likely due to the production of a reactive metabolite in some patients exhibiting a coumarin 7-hydroxylation deficiency).</AbstractText><CopyrightInformation>Copyright 1998 John Wiley & Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andréjak</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmacovigilance Regional Centre of Amiens, France. Amiens.chupharmacologie@wanadoo.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sgro</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Decocq</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hamel</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Morin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>10</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15073959</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1099-1557(199808)7:1+3.0.CO;2-1</ArticleId> </ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004031 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004031 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15073959
|texte= French pharmacovigilance survey evaluating the hepatic toxicity of coumarin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15073959" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |